SecBot SecBot
8-K ·Filed Sep 14, 2026

HRGN

Harvard Apparatus Regenerative Technology, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed1mo ago SEC0001437749-26-030244
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

The $2.84M raise provides working capital but at significant dilution to existing holders. Monitor for further cash needs and any progress on the company's stated goal of up-listing to a national exchange, which would likely require a reverse stock split.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d
HRGN ▲ +8.16% at T+20d
SHORT call ✗ call lost -8.16% · α vs SPY -5.65% · entry $1.96 → $2.12
Next anchor: T+60d in 6w
Latest observation: T+29 +9.92% FF3 residual α
Entry = T+0 close
Sep 14, 2026
via day close
T+1d
+17.35%
call -17.35% · α -17.81%
$2.30
settled 6w ago
T+5d
+14.80%
call -14.80% · α -14.44%
$2.25
settled 5w ago
T+20d
+8.16%
call -8.16% · α -5.65%
$2.12
settled 14d ago
T+60d
Pending
in 6w

Price Chart

Loading chart...

Executive Summary

Harvard Apparatus Regenerative Technology raised $2.84M via a private placement of 2,703,727 shares at $1.05/share, which closed on September 11, 2026. CEO Jerry (Junli) He participated by converting $717,911 of outstanding bridge notes into 683,725 shares at the same price, eliminating that debt. The filing is a routine capital raise with insider participation that clears near-term debt but dilutes existing holders by a substantial percentage, with no new operational catalysts disclosed.

Key Financial Metrics

Offering Size
$2.8M

Key Facts

  • Company raised $2,838,911 via private placement of 2,703,727 shares at $1.05/share
  • CEO Jerry (Junli) He converted $717,911 of bridge notes into 683,725 shares at same price
  • Private placement closed on September 11, 2026
  • Shares issued under Section 4(a)(2) and Rule 506 exemption
  • No cash proceeds from CEO's note conversion — debt extinguished in exchange for equity

Financial Impact

Dilutive equity raise of $2.84M at $1.05/share; CEO debt conversion of $717,911 eliminates near-term liability but adds to dilution

dilutiondebtcash

Risk Factors

  • Massive dilution from 2.7M new shares relative to likely low share count
  • OTC-traded micro-cap with no analyst coverage and 0% bullish consensus
  • No new business or pipeline catalysts disclosed

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-030244
Exhibit: ex_1015499.htm0001437749-26-030244
Document: hrgn20260911_8k.htm0001437749-26-030244
Document: 0001437749-26-030244-index-headers.html0001437749-26-030244
Document: 0001437749-26-030244-index.html0001437749-26-030244
Document: 0001437749-26-030244.txt0001437749-26-030244
4 reports for HRGN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for HRGN — sortable, filterable
TypeNow
Sep 14, 2026
6w ago
8-K
BEARISH ★ 5/10
$1.96 $2.12▼ −8.16%▼ −5.65%$1.96 (−0.10%)
Aug 3, 2026
12w ago
8-K
BEARISH ★ 5/10
$1.00 $1.58▼ −58.00%▼ −56.76%$1.96 (−96.20%)
Apr 28, 2026
25w ago
8-K
NEUTRAL ★ 4/10
$1.57 $1.30▼ −17.04%▼ −23.09%$1.96 (+25.21%)
Apr 15, 2026
27w ago
8-K
NEUTRAL ★ 5/10
$1.57 $1.50▼ −4.58%▼ −10.40%$1.96 (+24.81%)
Showing 4 of 4

US Market Status

Market Open — Closes in 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026